公开(公告)号：US20230085847A1

公开(公告)日：2023-03-23

申请号：US17933133

申请日：2022-09-19

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

公开(公告)号：US11377503B2

公开(公告)日：2022-07-05

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US20220135676A1

公开(公告)日：2022-05-05

申请号：US17530510

申请日：2021-11-19

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Benjamin ROSSI

IPC: C07K16/28 ,  C07K16/00 ,  C07K16/30

Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20220025045A1

公开(公告)日：2022-01-27

申请号：US17418271

申请日：2019-12-20

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.

公开(公告)号：US11208480B2

公开(公告)日：2021-12-28

申请号：US15321674

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Benjamin Rossi

IPC: C07K16/28 ,  C07K16/00 ,  C07K16/30

Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20210363249A1

公开(公告)日：2021-11-25

申请号：US17388059

申请日：2021-07-29

Applicant: INNATE PHARMA

Inventor： STEPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C12N5/12 ,  G01N33/574

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20210087270A1

公开(公告)日：2021-03-25

申请号：US17114835

申请日：2020-12-08

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20200325232A1

公开(公告)日：2020-10-15

申请号：US16765486

申请日：2018-11-19

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/68

Abstract: Multimeric multispecific proteins that bind multiple target antigens are provided. The proteins have particular advantages when configured to bind a NK or T cell activating receptor and one or two cancer associated antigens, and can be used in the treatment of disease, notably cancer.

公开(公告)号：US10766966B2

公开(公告)日：2020-09-08

申请号：US15517991

申请日：2015-10-09

Applicant: INNATE PHARMA

Inventor： Ivan Perrot ,  Carine Paturel ,  Laurent Gauthier

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C07K16/30

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US10675359B2

公开(公告)日：2020-06-09

申请号：US15702586

申请日：2017-09-12

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Patrick Dennler ,  Delphine Bregeon ,  Laurent Gauthier ,  François Romagné ,  Christian Belmant ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/68 ,  C07K16/00 ,  A61K47/60 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/50 ,  C07K19/00 ,  C12N9/10 ,  C12P21/00 ,  G01N33/68

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.